Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs JD.Com Inc (JD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs JD.Com Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while JD.Com Inc trades at $28.88 (market cap $38.39B). The key difference: Alnylam Pharmaceuticals, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | JD | |
|---|---|---|
Market Cap | $39.89B | $38.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $36.17 |
52-Week Low | $278.09 | $25.19 |
Enterprise Value | $38.15B | $24.55B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JD.com trades at $28.20, up 1.66% today, with a bullish technical signal from moving averages. The company reported revenue of $1.31 trillion in 2025, though net income fell to $19.63 billion, reducing the profit margin to 1.49%. Recent quarters show consistent earnings beats, and analyst sentiment is strongly positive with a consensus price target of $39.20. News highlights include a rally in Chinese tech stocks and ongoing legal investigations.
The outlook is supported by low valuation multiples and strong cash flow, but risks include regulatory scrutiny and margin pressure. Upside potential exists if earnings growth resumes, yet investor caution is warranted due to legal overhangs and competitive dynamics in e-commerce.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
